In order to avoid possible interactions with other drugs, particularly with Actonel, inform the physician or pharmacist about any other current treatment.
No formal interaction studies have been performed, however, no clinically relevant interactions with other medicinal products were found during clinical trials. In the risedronate sodium phase III osteoporosis studies with daily dosing, acetylsalicylic acid or NSAID use was reported by 33% and 45% of patients, respectively. In the phase III once-a-week study in postmenopausal women, acetylsalicylic acid or NSAID use was reported by 57% and 40% of patients, respectively. Among regular acetylsalicylic acid or NSAID users (≥3 days per week), the incidence of upper gastrointestinal adverse events in risedronate sodium-treated patients was similar to that in control patients.
If considered appropriate, Actonel may be used concomitantly with oestrogen supplementation.
Concomitant ingestion of medications containing polyvalent cations (eg, calcium, magnesium, iron and aluminium) will interfere with the absorption of Actonel (see Warnings). These products should be taken at a different time of the day from that of the Actonel dose (see Dosage & Administration).
Risedronate sodium is not systemically metabolised, does not induce cytochrome P-450 enzymes and has low protein-binding.